

# Mads Agerbæk

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11529321/publications.pdf>

Version: 2024-02-01

21  
papers

1,526  
citations

516710

16  
h-index

752698

20  
g-index

21  
all docs

21  
docs citations

21  
times ranked

2310  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1547-1557.	1.6	298
2	Surveillance for Stage I Nonseminoma Testicular Cancer: Outcomes and Long-Term Follow-Up in a Population-Based Cohort. <i>Journal of Clinical Oncology</i> , 2014, 32, 3817-3823.	1.6	189
3	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. <i>European Urology</i> , 2016, 70, 75-82.	1.9	174
4	Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. <i>European Urology</i> , 2017, 71, 961-969.	1.9	154
5	A Nationwide Cohort Study of Stage I Seminoma Patients Followed on a Surveillance Program. <i>European Urology</i> , 2014, 66, 1172-1178.	1.9	151
6	Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. <i>European Urology</i> , 2018, 73, 535-540.	1.9	112
7	Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. <i>Brain Imaging and Behavior</i> , 2017, 11, 769-783.	2.1	65
8	Normal tissue sparing in a phase II trial on daily adaptive plan selection in radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2014, 53, 997-1004.	1.8	59
9	Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 584-592.	1.6	52
10	Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients. <i>Scientific Reports</i> , 2018, 8, 1917.	3.3	50
11	Cognitive impairment in testicular cancer survivors 2 to 7 years after treatment. <i>Supportive Care in Cancer</i> , 2015, 23, 2973-2979.	2.2	37
12	Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma. <i>Cancer</i> , 2017, 123, 1212-1218.	4.1	36
13	Cognitive impairment and potential biological and psychological correlates of neuropsychological performance in recently orchiectomized testicular cancer patients. <i>Psycho-Oncology</i> , 2015, 24, 1174-1180.	2.3	34
14	Late Relapses in Stage I Testicular Cancer Patients on Surveillance. <i>European Urology</i> , 2016, 70, 365-371.	1.9	34
15	Intra-fractional bladder motion and margins in adaptive radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2015, 54, 1461-1466.	1.8	26
16	The Danish Testicular Cancer database. <i>Clinical Epidemiology</i> , 2016, Volume 8, 703-707.	3.0	21
17	Long-term neurotoxicity and quality of life in testicular cancer survivors—a nationwide cohort study. <i>Journal of Cancer Survivorship</i> , 2021, 15, 509-517.	2.9	15
18	Ten years of experience with MRI follow-up of testicular cancer stage I: a retrospective study and an MRI protocol with DWI. <i>Acta Oncologica</i> , 2020, 59, 1374-1381.	1.8	8

#	ARTICLE	IF	CITATIONS
19	Surgery After Relapse in Stage I Nonseminomatous Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2322-2322.	1.6	6
20	Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in newly orchiectomized testicular cancer patients. <i>Brain Imaging and Behavior</i> , 2022, 16, 199-210.	2.1	5
21	Reply to C. Rusner et al, L.C. Pagliaro et al, and K. Lu. <i>Journal of Clinical Oncology</i> , 2015, 33, 2326-2327.	1.6	0